APA (7th ed.) Citation

H, A., B, S., MJ, A., H, A., R, B., MA, S., . . . Y, A. (2023). COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study. Journal of thrombosis and thrombolysis, 56(3), 447. https://doi.org/10.1007/s11239-023-02860-4

Chicago Style (17th ed.) Citation

H, Abdel-Razeq, et al. "COMPASS-CAT Versus Khorana Risk Assessment Model for Predicting Venous Thromboembolic Events in Patients with Non-small Cell Lung Cancer on Active Treatment with Chemotherapy And/or Immunotherapy, the CK-RAM Study." Journal of Thrombosis and Thrombolysis 56, no. 3 (2023): 447. https://doi.org/10.1007/s11239-023-02860-4.

MLA (9th ed.) Citation

H, Abdel-Razeq, et al. "COMPASS-CAT Versus Khorana Risk Assessment Model for Predicting Venous Thromboembolic Events in Patients with Non-small Cell Lung Cancer on Active Treatment with Chemotherapy And/or Immunotherapy, the CK-RAM Study." Journal of Thrombosis and Thrombolysis, vol. 56, no. 3, 2023, p. 447, https://doi.org/10.1007/s11239-023-02860-4.